GSK plc announced that the US FDA has accepted its prefilled syringe application for the Shingrix shingles vaccine, expected for a decision by June 20, 2025, enhancing convenience for healthcare providers. Over 90 million doses have been distributed in the US since 2017, addressing a significant health need as one million people develop shingles annually.